RED+BLUE STRATEGIES for CIGNA CORPORATION
What was lobbied
3 issue areas, each in the filer's own words, with who lobbied on it and where.
Pharmacy PHA
Issues related to Trump Administration proposals and regulations regarding drug pricing reforms, regulations regarding rebates, and related guidances focused on affordability and accessibility to prescription medications in the United States. Proposals, guidances and call letters and impacting Medicare Part D and the role of Pharmacy Benefit Managers. Issues related to transparency in the prescription drug marketplaces including new technologies to improve physician and patient access to real time pricing questions and concerns. Issues related to utilization and access to e- prescribing tools. Issues focused on the promotion of fair competition in the prescription drug market place, including policies focused on patents, biosimilars and generic medications.
| Lobbyist | Covered position, as disclosed |
|---|---|
| MEGAN HAUCK MARSHALL | — |
| MELANIE JAN NATHANSON | — |
Health Issues HCR
Issues related to Trump Administration proposals and regulations regarding drug pricing reforms, regulations regarding rebates, and related guidances focused on affordability and accessibility to prescription medications in the United States. Proposals, guidances and call letters and impacting Medicare Part D and the role of Pharmacy Benefit Managers. Issues related to transparency in the prescription drug marketplaces including new technologies to improve physician and patient access to real time pricing questions and concerns. Issues related to utilization and access to e- prescribing tools. Issues focused on the promotion of fair competition in the prescription drug market place, including policies focused on patents, biosimilars and generic medications.
| Lobbyist | Covered position, as disclosed |
|---|---|
| MEGAN HAUCK MARSHALL | — |
| MELANIE JAN NATHANSON | — |
Medicare/Medicaid MMM
Proposals, guidances and call letters and impacting Medicare Part D and the role of Pharmacy Benefit Managers. Issues related to transparency in the Medicare prescription drug marketplace, including new technologies to improve physician and patient access to real time pricing questions and concerns.
| Lobbyist | Covered position, as disclosed |
|---|---|
| MEGAN HAUCK MARSHALL | — |
| MELANIE JAN NATHANSON | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.